🔎 Trials Near Me

Hjem › Atopisk dermatitis (eczem) › Maryland

Atopisk dermatitis (eczem) kliniske forsøg i Maryland

16 studier for Atopisk dermatitis (eczem) søger deltagere på steder i Maryland.

Byer i Maryland

Officiel studietekst (engelsk)

Natural History and Genetics of Food Allergy and Related Conditions

  • National Institutes of Health Clinical Center, Bethesda
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
1 Day – 99 Years · Alle køn · Opdateret 2. okt. 2026 · NCT02504853

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

  • National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1
Alder 12 til 120 · Alle køn · Opdateret 2. okt. 2026 · NCT07262983

Effects of Treatments on Atopic Dermatitis

  • National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2Frivillige med god helbredstilstand velkomne
Alder 2 til 50 · Alle køn · Opdateret 28. sep. 2026 · NCT01631617

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

  • Investigational Site, Rockville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07003425

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

  • National Institutes of Health Clinical Center, Bethesda
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 til 75 · Alle køn · Opdateret 22. sep. 2026 · NCT04864886

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

  • National Institutes of Health Clinical Center, Bethesda
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 2 til 100 · Alle køn · Opdateret 16. sep. 2026 · NCT00605878

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

  • U.S. Dermatology Partners Rockville, Rockville
RekruttererObservationsstudie
Alder 12 til 89 · Alle køn · Opdateret 15. sep. 2026 · NCT07645820

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  • Chesapeake Clinical Research, Inc, Pasadena
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 28. aug. 2026 · NCT07599813

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

  • National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2
Alder 3 til 21 · Alle køn · Opdateret 26. aug. 2026 · NCT03835767

Cardamom and Topical Roseomonas in Atopic Dermatitis

  • National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2
Alder 2 til 100 · Alle køn · Opdateret 13. aug. 2026 · NCT06096857

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

  • National Institutes of Health Clinical Center, Bethesda
RekruttererObservationsstudie
Alder 3 til 100 · Alle køn · Opdateret 17. jul. 2026 · NCT06732414

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  • Maryland Laser Skin and Vein, Hunt Valley
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 4. maj 2026 · NCT05995964

Dupilumab De-escalation in Pediatric Atopic Dermatitis

  • Johns Hopkins Univerisity, Baltimore
RekruttererFase 4
Alder 1 til 17 · Alle køn · Opdateret 20. apr. 2026 · NCT06116526

Registry for Systemic Eczema Treatments

  • Johns Hopkins University, Baltimore
RekruttererObservationsstudie
Alder 1 til 26 · Alle køn · Opdateret 7. apr. 2026 · NCT06136767

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

  • Galderma Investigational Site 7098, Columbia
  • Galderma Investigational Site 8012, Glenn Dale
  • Galderma Investigational Site 7068, Rockville
RekruttererObservationsstudie
Alder 12 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT06988605

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.